Compare GRDX & ARAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRDX | ARAY |
|---|---|---|
| Founded | N/A | 1990 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 31.3M |
| IPO Year | 2016 | 2006 |
| Metric | GRDX | ARAY |
|---|---|---|
| Price | $4.99 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.9K | ★ 1.9M |
| Earning Date | 11-18-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 21.95 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.75 |
| Revenue Next Year | N/A | $2.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.87 | $0.12 |
| 52 Week High | $6.93 | $1.46 |
| Indicator | GRDX | ARAY |
|---|---|---|
| Relative Strength Index (RSI) | 54.68 | 32.18 |
| Support Level | $2.37 | N/A |
| Resistance Level | $5.04 | $0.29 |
| Average True Range (ATR) | 0.58 | 0.02 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 44.09 | 12.57 |
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.